Gemcitabine  Chemical Structure

Gemcitabine Chemical Structure
Molecular Weight: 263.2

Validation & Quality Control

Customer Product Validation(3)

Quality Control & MSDS

Related Compound Libraries

Gemcitabine is available in the following compound libraries:

Product Information

  • Compare DNA/RNA Synthesis Inhibitors
    Compare DNA/RNA Synthesis Products
  • Research Area

Product Description

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYS4TZNUUUN3ME2wMlAxODR3ODDuUS=>MkW3V2FPT0WU
ES4MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{O5c2lEPTB;MD6wNFA3PTNibl2=M120[HNCVkeHUh?=
ACHNNH[3S4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfmRVRqUUN3ME2wMlAxODh6NzDuUS=>NH[yUHdUSU6JRWK=
KYSE-510NVLERZRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XDOGlEPTB;MD6wNFA6PzVibl2=MlPCV2FPT0WU
EW-7M1PqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnj3TWM2OD1yLkCwNlU5KG6PM2H4VnNCVkeHUh?=
BFTC-905M3\xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTBwMEC1NVUhdk1?MVPTRW5ITVJ?
KE-37MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{X6ZWlEPTB;MD6wNFU3OSCwTR?=MlT3V2FPT0WU
SBC-5NHGzUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LQT2lEPTB;MD6wNFU4KG6PNVLN[5l5W0GQR1XS
NKM-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTBwMEC3NFkhdk1?NXPyXoJQW0GQR1XS
RH-1NFvW[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1:4UmlEPTB;MD6wNFcyQCCwTR?=NFH6NWdUSU6JRWK=
ALL-PONUH1[ldoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTBwMEC4N{BvVQ>?MXfTRW5ITVJ?
QIMR-WILNIfvfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrEdYJKSzVyPUCuNFA5QTRibl2=M2fkWHNCVkeHUh?=
A375NFrsTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfuTWM2OD1yLkCwPVk2KG6PM2fKbXNCVkeHUh?=
SIG-M5NFfre|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTBwMEGwOEBvVQ>?MYPTRW5ITVJ?
KGNNEPOfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTBwMEGwPEBvVQ>?NELwRppUSU6JRWK=
EW-13MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jvfmlEPTB;MD6wNVEzKG6PNFXiVWJUSU6JRWK=
NCI-SNU-1MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUWxcW9nUUN3ME2wMlAyPiCwTR?=MUHTRW5ITVJ?
PSN1NV\0PZE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1v2WWlEPTB;MD6wNVY2KG6PNIDrdGlUSU6JRWK=
HUTU-80NIrTcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTBwMEG2OkBvVQ>?MoroV2FPT0WU
EW-16M2SwSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1PHWWlEPTB;MD6wNlMhdk1?NIDWOlVUSU6JRWK=
786-0MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIC3cFdKSzVyPUCuNFI{KG6PMnrHV2FPT0WU
ES1NELtRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVPBVFBvUUN3ME2wMlAzPjhibl2=NUHTb4M5W0GQR1XS
RKOMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTBwMEK3PUBvVQ>?NIWzfmJUSU6JRWK=
ESS-1NXjkN|k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3XnR2lEPTB;MD6wNlg3KG6PM3X1VHNCVkeHUh?=
SK-UT-1MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTBwMEK5O{BvVQ>?MnHzV2FPT0WU
LB2241-RCCNH63c4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTBwMEOxPEBvVQ>?MoWzV2FPT0WU
CHL-1Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrsW29KSzVyPUCuNFMzPCCwTR?=MV3TRW5ITVJ?
SW1783MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\KVZZKSzVyPUCuNFM{PiCwTR?=MVPTRW5ITVJ?
MEL-JUSOMlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fjRmlEPTB;MD6wN|kyKG6PMVLTRW5ITVJ?
HT-29NIPtTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jVZWlEPTB;MD6wOFE{KG6PNVjaW2JoW0GQR1XS
SNG-MM4rSZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofoTWM2OD1yLkC0NlUhdk1?MnjOV2FPT0WU
TE-15MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3S5WWlEPTB;MD6wOFY1KG6PNHi3N5pUSU6JRWK=
HOSNVPBV3RUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHsRYtKSzVyPUCuNFQ5KG6PNX71SoVnW0GQR1XS
BB65-RCCMlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrRW49KSzVyPUCuNFUyOiCwTR?=NGXwTnFUSU6JRWK=
HCE-4MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moj4TWM2OD1yLkC1Nlghdk1?MUfTRW5ITVJ?
MHH-ES-1NWrRb2NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrTOY9zUUN3ME2wMlA2OzFibl2=NGfRTJFUSU6JRWK=
RPMI-7951NIDUclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHKTWM2OD1yLkC1OFEhdk1?MmXlV2FPT0WU
IST-SL2NH\QWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnBTWM2OD1yLkC1PFQhdk1?MVTTRW5ITVJ?
CMKM1nqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDGcoprUUN3ME2wMlA2QDZibl2=NHjEUVhUSU6JRWK=
GR-STNHjo[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHlTWM2OD1yLkC1PVUhdk1?NHXZR4pUSU6JRWK=
NALM-6M{\jNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M13YcWlEPTB;MD6wOlIzKG6PNYjYZodUW0GQR1XS
RPMI-6666NGnvbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfOWm11UUN3ME2wMlA3PTJibl2=MYHTRW5ITVJ?
LC-2-adM{GwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTBwME[1N{BvVQ>?MlXPV2FPT0WU
ARH-77MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTBwMEexNUBvVQ>?M2jPVHNCVkeHUh?=
IST-MEL1NV7xPIJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTjTWM2OD1yLkC3NlYhdk1?MULTRW5ITVJ?
SW1710M4S5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTBwMEe1NUBvVQ>?M1HIVnNCVkeHUh?=
DELNX36d25WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3UWYVXUUN3ME2wMlA5QDdibl2=NIHxOXpUSU6JRWK=
AGSNGTpeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2X1T2lEPTB;MD6wPVAzKG6PMljmV2FPT0WU
NCI-H2122NUfV[XB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXu1dHh1UUN3ME2wMlA6PDZibl2=M17pfXNCVkeHUh?=
HSC-4NIXBfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfPTIg1UUN3ME2wMlExOiCwTR?=M{S5WnNCVkeHUh?=
AM-38MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLaRW5XUUN3ME2wMlEzOSCwTR?=MYrTRW5ITVJ?
769-PNUjieW5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn75TWM2OD1yLkGyN{BvVQ>?MWHTRW5ITVJ?
RT-112M3nLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGTNR2FKSzVyPUCuNVI4KG6PMXrTRW5ITVJ?
MCF7NIfm[JZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEi1cWtKSzVyPUCuNVM3KG6PNUL6e3VNW0GQR1XS
IGROV-1M4DIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4iycGlEPTB;MD6xOFUhdk1?M2TJN3NCVkeHUh?=
OCI-AML2NWfWNWw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTBwMUS3JI5ONXjoXFlIW0GQR1XS
NCI-H1299M4[xeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEC3UFVKSzVyPUCuNVU4KG6PNY\CWWtiW0GQR1XS
A431M{jhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVG3VlFYUUN3ME2wMlE5OyCwTR?=MYTTRW5ITVJ?
SW982NIPSepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVi5VWE3UUN3ME2wMlIyOyCwTR?=NFqwRWVUSU6JRWK=
BB30-HNCMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoO4TWM2OD1yLkKzNUBvVQ>?M3HRfnNCVkeHUh?=
ACNMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXPTWM2OD1yLkK0OEBvVQ>?MVrTRW5ITVJ?
647-VNUHY[3FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O3XmlEPTB;MD6yOFghdk1?M1y0RnNCVkeHUh?=
SK-PN-DWMlTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTBwMk[2JI5OMXnTRW5ITVJ?
LCLC-97TM1NFXQ[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFT4XHdKSzVyPUCuNlY4KG6PNHz1U5pUSU6JRWK=
LB1047-RCCM1[yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvjO5Y5UUN3ME2wMlI3QSCwTR?=M3LVNnNCVkeHUh?=
A2780MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTBwMkegcm0>NF7GUXVUSU6JRWK=
C-33-ANYnJRlZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfoTIFKSzVyPUCuNlc{KG6PM3XURnNCVkeHUh?=
NCI-H2228NVP0cnROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjBcWhrUUN3ME2wMlMyPCCwTR?=MX\TRW5ITVJ?
TE-5NE\jVmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XE[WlEPTB;MD6zNVYhdk1?NVrpTWw{W0GQR1XS
HC-1MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFKwXZZKSzVyPUCuN|I4KG6PNEe3[VlUSU6JRWK=
SK-MES-1M4rmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XQ[WlEPTB;MD6zNlghdk1?NX3iNINrW0GQR1XS
NCI-H1355NUXuXJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PtfGlEPTB;MD6zPFEhdk1?MXHTRW5ITVJ?
YKG-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYP3TXZOUUN3ME2wMlQyQSCwTR?=NGjmZpFUSU6JRWK=
RS4-11MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXFSoRPUUN3ME2wMlQ{OyCwTR?=M{ToVHNCVkeHUh?=
DaoyNIq1W29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXUTWM2OD1yLkS1OkBvVQ>?M3zIU3NCVkeHUh?=
A3-KAWNW\XTXBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXj3UGVZUUN3ME2wMlU2OSCwTR?=MlPvV2FPT0WU
SK-MEL-30NUG3ZoNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTBwNUW0JI5OMl7NV2FPT0WU
U031Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojhTWM2OD1yLkW2OUBvVQ>?MVnTRW5ITVJ?
SK-LMS-1NFTMNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYK0OGZEUUN3ME2wMlU4QCCwTR?=NV3KWmZUW0GQR1XS
ES6MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDqNppIUUN3ME2wMlU5PiCwTR?=M173fnNCVkeHUh?=
EoL-1-cellMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITiPZpKSzVyPUCuOlE3KG6PM{jqenNCVkeHUh?=
NCI-H2009M{jETmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjBTWM2OD1yLk[xPUBvVQ>?MmmyV2FPT0WU
A4-FukM1;Oe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPYUHk3UUN3ME2wMlYzPiCwTR?=M{nYenNCVkeHUh?=
KYSE-270M1;Sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXDUoFVUUN3ME2wMlY{PCCwTR?=M2TWd3NCVkeHUh?=
SK-LU-1M{nWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHhTWM2OD1yLk[1OUBvVQ>?Mn:yV2FPT0WU
SW872NXPsT5J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrOU|RKSzVyPUCuO|Y2KG6PNWX6[oRFW0GQR1XS
ES8MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjLTohMUUN3ME2wMlc5KG6PM1rKT3NCVkeHUh?=
G-402MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn3pTWM2OD1yLke4OEBvVQ>?MWPTRW5ITVJ?
ATN-1M{\IVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33seWlEPTB;MD64NFchdk1?M3X0WnNCVkeHUh?=
DoTc2-4510NUnSfXVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjiOIM5UUN3ME2wMlkxOSCwTR?=NFruVmdUSU6JRWK=
MES-SAMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXKTWM2OD1yLkmwOUBvVQ>?NX\SdpAxW0GQR1XS
SF268NVrVZ|NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPReFlCUUN3ME2wMlkzPyCwTR?=M{\jUnNCVkeHUh?=
SF539NFTtZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIiw[nBKSzVyPUGuNFIhdk1?NVTUZpJjW0GQR1XS
NB69MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XLbGlEPTB;MT6wOUBvVQ>?NV7kdZFmW0GQR1XS
8505CMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjidXpKSzVyPUGuNFYhdk1?NGLmPZlUSU6JRWK=
CAL-12TNXfrTY9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF36[2FKSzVyPUGuNFghdk1?M4nMOXNCVkeHUh?=
BHYM4fMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTFwMUSgcm0>NXjoVGVzW0GQR1XS
LB647-SCLCM3PadGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\VOGhKSzVyPUGuNVghdk1?MWrTRW5ITVJ?
CAL-62MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm3SJFKSzVyPUGuNlIhdk1?NXfLR5gyW0GQR1XS
MEG-01MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTFwMkegcm0>MXrTRW5ITVJ?
MG-63MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWTpO49zUUN3ME2xMlM{KG6PNGnIfGlUSU6JRWK=
SW620NVPvOYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LjZWlEPTB;MT6zOUBvVQ>?Mnr3V2FPT0WU
A388NFH2RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7HVIMzUUN3ME2xMlM3KG6PNITibpBUSU6JRWK=
BCPAPMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjveVJKSzVyPUGuOFUhdk1?Mlz5V2FPT0WU
P30-OHKMnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofMTWM2OD1zLkS2JI5OMX\TRW5ITVJ?
Ca9-22MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnyTWM2OD1zLkW0JI5ONFLXe4RUSU6JRWK=
VMRC-RCZMlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnNeVRKSzVyPUGuOVQhdk1?MkG2V2FPT0WU
LOXIMVIMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTlNVlKSzVyPUGuOkBvVQ>?NXvMW|Z1W0GQR1XS
L-540MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{\GSmlEPTB;MT62JI5OMkPnV2FPT0WU
NTERA-S-cl-D1NIW1SHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTrZnVKSzVyPUGuOlQhdk1?MYHTRW5ITVJ?
MFH-inoM{PIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;Od2lEPTB;MT62OkBvVQ>?MWDTRW5ITVJ?
Calu-6Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlTGTWM2OD1zLkezJI5ONILKUnJUSU6JRWK=
HELNHXkSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzL[JBOUUN3ME2xMlc6KG6PM1zYV3NCVkeHUh?=
CAL-33MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2H2S2lEPTB;MT64PUBvVQ>?NVTDSnRPW0GQR1XS
HSC-3MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULlbGRNUUN3ME2xMlkyKG6PMYTTRW5ITVJ?
KU812MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3vsdGlEPTB;MT65NUBvVQ>?NX;w[JlPW0GQR1XS
EB2NETaPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIm2b3hKSzVyPUKuNFEhdk1?NILwN21USU6JRWK=
SRMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTJwMUKgcm0>NWmzWFJJW0GQR1XS
NCI-H2087NYLFOIJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTJwMUSgcm0>NUnhW285W0GQR1XS
H4MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jYVWlEPTB;Mj6xPEBvVQ>?MYjTRW5ITVJ?
EW-1MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPvSYlKSzVyPUKuNlIhdk1?MUTTRW5ITVJ?
MC-IXCMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3oemNKSzVyPUKuNlYhdk1?NWnVbo9KW0GQR1XS
NCI-H727NVznO5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPxTWM2OD1{LkWxJI5OMXnTRW5ITVJ?
MRK-nu-1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjGcJZKSzVyPUKuOVchdk1?MoH3V2FPT0WU
COLO-668MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjFcpE2UUN3ME2yMlY3KG6PMmHwV2FPT0WU
CGTH-W-1MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\tSpF5UUN3ME2yMlczKG6PMXfTRW5ITVJ?
CHP-212NWTERVJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fJe2lEPTB;Mj63OUBvVQ>?Moq2V2FPT0WU
GI-1NHGweItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTJwN{[gcm0>NGHGc2VUSU6JRWK=
HCC1806MljTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\CTWM2OD1{LkmxJI5OM3HOfHNCVkeHUh?=
HLENF64WWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\0TWM2OD1|IH7NNFrsR|lUSU6JRWK=
HSC-2MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfRTWM2OD1|LkCzJI5OMX3TRW5ITVJ?
DMS-273NIrCfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFPP[XdKSzVyPUOuNFchdk1?MljBV2FPT0WU
DU-4475M1jJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnQVG1KSzVyPUOuNVQhdk1?M33zOHNCVkeHUh?=
LXF-289NWDl[2lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFj0N|JKSzVyPUOuN|Ehdk1?NFnafZlUSU6JRWK=
PANC-03-27NE\qSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\lUopKSzVyPUOuOVEhdk1?MULTRW5ITVJ?
GAMGNWXCb3B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTNwN{Sgcm0>MUfTRW5ITVJ?
NCI-H522M3naXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjrZm9pUUN3ME20MlM1KG6PNGfC[HZUSU6JRWK=
SW626NHfLNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkXrTWM2OD12LkS2JI5OMni3V2FPT0WU
HT-144MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nhRWlEPTB;ND65NkBvVQ>?M4X5RXNCVkeHUh?=
MEL-HOMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUn3SpV5UUN3ME21MlE3KG6PMXfTRW5ITVJ?
BE-13M{PtS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2KwdGlEPTB;NT6yNUBvVQ>?NVjj[|dkW0GQR1XS
VA-ES-BJMnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHrbpVUUUN3ME21MlI3KG6PMWHTRW5ITVJ?
NCI-H441NFvye5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFzvUmRKSzVyPUWuOkBvVQ>?M3XsSHNCVkeHUh?=
KP-4Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfyWWdKSzVyPUWuOlEhdk1?MXvTRW5ITVJ?
LoVoM37IT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTVwN{Ggcm0>NU\MRmNYW0GQR1XS
HT-1080MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXGTWM2OD13LkizJI5ONYHodZpQW0GQR1XS
GB-1MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInyemlKSzVyPUWuPFQhdk1?NXzBbo1nW0GQR1XS
IA-LMMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{nRSmlEPTB;NT65NUBvVQ>?NEfPW4FUSU6JRWK=
8-MG-BAMkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\sWmlEPTB;NT65N{BvVQ>?MoTIV2FPT0WU
SK-HEP-1MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXz1dYJLUUN3ME22MlE1KG6PMn;uV2FPT0WU
697M4mzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3KTWM2OD14LkK1JI5OMlHtV2FPT0WU
KYSE-450NWrMfXNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfpTWM2OD14LkOyJI5ONU\PUmszW0GQR1XS
HCC2998NGLFOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDEPFV[UUN3ME22MlM1KG6PNGLVXmFUSU6JRWK=
HD-MY-ZMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjndZpKSzVyPU[uOlghdk1?MoPyV2FPT0WU
OS-RC-2NHfJN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHn2c5JKSzVyPU[uOlghdk1?NIHDRWpUSU6JRWK=
SF126M3\EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTdwMEWgcm0>MXrTRW5ITVJ?
Ca-SkiNHvobXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{D5b2lEPTB;Nz6wPUBvVQ>?NGq0[GRUSU6JRWK=
NCI-H358MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2WwXWlEPTB;Nz6xOkBvVQ>?MorUV2FPT0WU
J82M2PwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTdwNEGgcm0>NHfWWoRUSU6JRWK=
NCI-H2342MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTdwNkOgcm0>NFz3S5dUSU6JRWK=
OVCAR-8MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH32OZdKSzVyPUeuPUBvVQ>?M1LxT3NCVkeHUh?=
TE-8NFvZXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRThibl2=M4rEXnNCVkeHUh?=
ETK-1NWDSSmU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHDTWM2OD16LkC4JI5ONHrlW2dUSU6JRWK=
HAL-01M{HpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3PXdWlEPTB;OD6yJI5ONHX6U29USU6JRWK=
KYSE-150NG\CWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXKxOGV1UUN3ME24MlQ4KG6PNVPkOIlFW0GQR1XS
NCI-H810M2rv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;odWlEPTB;OD61OkBvVQ>?MVLTRW5ITVJ?
ONS-76MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRThwNkigcm0>M2rPN3NCVkeHUh?=
NMC-G1MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUThSoFkUUN3ME24Mlc3KG6PMlXZV2FPT0WU
C3ANYSzTGRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33id2lEPTB;OD64OEBvVQ>?M4PPUnNCVkeHUh?=
PA-1M3f6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1y4TGlEPTB;OD65PUBvVQ>?M2\vd3NCVkeHUh?=
SH-4Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLpTWM2OD17LkCyJI5OM163cXNCVkeHUh?=
EFO-27MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fSSWlEPTB;OT6wOUBvVQ>?M2rxfnNCVkeHUh?=
CAPAN-1MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2S4U2lEPTB;OT6yN{BvVQ>?NInvfW5USU6JRWK=
DU-145MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXJTJdKSzVyPUmuNlkhdk1?NYXpVpFjW0GQR1XS
A101DM{j0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX64dFlFUUN3ME25MlM4KG6PMmTQV2FPT0WU
ST486NVe4bpVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF7le4lKSzVyPUmuOFEhdk1?M{XSc3NCVkeHUh?=
NCI-H1437NV;DbJN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\sOGlEPTB;OT60NkBvVQ>?MX3TRW5ITVJ?
HGC-27NE[2TZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTlwNjDuUS=>MV\TRW5ITVJ?
8305CM2q0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTlwNkSgcm0>MoLPV2FPT0WU
OCUB-MNIHHbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTFyLkCzJI5OMX7TRW5ITVJ?
COLO-679NHfNSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1[2emlEPTB;MUCuNFchdk1?MVPTRW5ITVJ?
Detroit562NHrle3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3X3ZmlEPTB;MUCuOFIhdk1?NInET|hUSU6JRWK=
A204NHjWV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2Tq[mlEPTB;MUGuNVYhdk1?MkLIV2FPT0WU
NCI-H1734MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPqVG9KSzVyPUGxMlI6KG6PM1jTVXNCVkeHUh?=
MC-CARMlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3tNmw3UUN3ME2xNU42QCCwTR?=NIXoVotUSU6JRWK=
NCI-H2170NUHT[HlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\KOIlpUUN3ME2xNU46PyCwTR?=NGC3[ohUSU6JRWK=
NCI-SNU-5MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGf3[GxKSzVyPUGyMlE{KG6PNVfXU4JZW0GQR1XS
HCE-TMmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzxZW5LUUN3ME2xNk41OiCwTR?=NHzmSI1USU6JRWK=
KYSE-180M3zTZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTF{LkixJI5OMlfxV2FPT0WU
C8166NWLJe5p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWizc2pGUUN3ME2xN{4xQCCwTR?=MYrTRW5ITVJ?
NCI-H460MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlraTWM2OD1zMz61OEBvVQ>?MVfTRW5ITVJ?
SNU-449MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2O5emlEPTB;MUOuO|chdk1?M2LKdnNCVkeHUh?=
MDA-MB-468NHPFcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{P5PGlEPTB;MUSuNVIhdk1?NIjqbZpUSU6JRWK=
COR-L23NFT3dWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVmxeWxNUUN3ME2xOE4yOyCwTR?=MlntV2FPT0WU
CTV-1NHjaU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTF2LkG0JI5OMX7TRW5ITVJ?
BL-41MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\SPGlEPTB;MUSuN|chdk1?M{L3ZXNCVkeHUh?=
IGR-1MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV:zWXc2UUN3ME2xOE41OiCwTR?=NHXWdJFUSU6JRWK=
TK10MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjTU5FKSzVyPUG0MlQ6KG6PMmLpV2FPT0WU
REHMn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUGxU3JpUUN3ME2xOE42OSCwTR?=NVS2[ZhuW0GQR1XS
LU-139M2HlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTWTWM2OD1zND61PUBvVQ>?NIPLSYVUSU6JRWK=
KP-N-YSM3zqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fEdGlEPTB;MUSuPVchdk1?M2m2cnNCVkeHUh?=
PANC-10-05NGLl[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHO5W2VKSzVyPUG1MlM5KG6PNIO1NoZUSU6JRWK=
HL-60M2K2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rKbGlEPTB;MUWuOlkhdk1?NWrwSGxIW0GQR1XS
T84MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrnN4ZiUUN3ME2xOU46PiCwTR?=MkjUV2FPT0WU
RPMI-8226MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnzV|JNUUN3ME2xOk4xOiCwTR?=NIjEUohUSU6JRWK=
UM-UC-3MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XEN2lEPTB;MU[uNVYhdk1?NW\nU3pTW0GQR1XS
TE-10NXzo[Zc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LONmlEPTB;MU[uNlEhdk1?Mn3qV2FPT0WU
CAL-148MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DUcWlEPTB;MUeuNlMhdk1?MUjTRW5ITVJ?
BV-173NWfqZ5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTF5LkK3JI5ONFXXb3JUSU6JRWK=
Calu-3M1TNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXe0e245UUN3ME2xO{4zQSCwTR?=NG[2ZnlUSU6JRWK=
RPMI-2650MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;Ke4VKSzVyPUG3MlU6KG6PMX3TRW5ITVJ?
MKN45MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPrfnIyUUN3ME2xO{44OyCwTR?=MUnTRW5ITVJ?
NUGC-3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzrO2pHUUN3ME2xPE4{PCCwTR?=MlTKV2FPT0WU
NCI-H520M3fSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTF6Lke3JI5OMY\TRW5ITVJ?
CCRF-CEMM2myNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1;TcWlEPTB;MUiuPFUhdk1?MX7TRW5ITVJ?
NCI-H2405M{O0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTnNIU2UUN3ME2xPU4yKG6PNUjBO215W0GQR1XS
ES7NIP0fGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPJboVKSzVyPUG5Mlc3KG6PMnfqV2FPT0WU
BPH-1NX:wN|lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTPTWM2OD1{MD6yPEBvVQ>?MmC4V2FPT0WU
SASMnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\mN3pHUUN3ME2yNE42KG6PNEP5dXpUSU6JRWK=
HuCCT1NEjtV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jFT2lEPTB;MkCuOVghdk1?NGTMNYFUSU6JRWK=
LOUCYMoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;uPWlEPTB;MkCuOlYhdk1?M2XCOnNCVkeHUh?=
NCI-H292MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2f0OGlEPTB;MkCuO|khdk1?MkWyV2FPT0WU
G-361M2\hR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\WRWlEPTB;MkGuNFchdk1?NG\6RXdUSU6JRWK=
M059JMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPxUopyUUN3ME2yNU4xQCCwTR?=NGPaTI5USU6JRWK=
NCI-H1651NUf5[HZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LPW2lEPTB;MkGuNVEhdk1?MnvIV2FPT0WU
KALS-1Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXETWM2OD1{MT6zPUBvVQ>?NHm2NnFUSU6JRWK=
DJM-1MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTJzLkW5JI5ONIDBfYFUSU6JRWK=
AU565MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfpSFFKSzVyPUKxMlg{KG6PMn\pV2FPT0WU
HCC38MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTJzLkm1JI5OMonZV2FPT0WU
U251NIL0bGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXXbXJKSzVyPUKyMlI4KG6PMYDTRW5ITVJ?
ABC-1M1;Sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTx[IdKSzVyPUKyMlY2KG6PMkjDV2FPT0WU
SK-NEP-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPvRoRKSzVyPUKyMlk{KG6PMXfTRW5ITVJ?
CESSNXjmSIg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm[3TWM2OD1{Mz6xPUBvVQ>?NH30R4tUSU6JRWK=
MIA-PaCa-2MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrFZVhLUUN3ME2yN{4{PiCwTR?=NV7MPWZ3W0GQR1XS
SUP-T1MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPnd5ZmUUN3ME2yN{41PyCwTR?=MkW0V2FPT0WU
L-428MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkP1TWM2OD1{Mz62NkBvVQ>?M1LZRXNCVkeHUh?=
SW954NI\mZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHsd|NKSzVyPUKzMlY5KG6PNIHTUGRUSU6JRWK=
HO-1-N-1Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTueohFUUN3ME2yN{44PyCwTR?=M3Xi[XNCVkeHUh?=
CHP-126M3XROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTJ2LkG0JI5OMnPuV2FPT0WU
HMV-IIMmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTJ2LkO0JI5ONFTDWoVUSU6JRWK=
NB10NUHTN2FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;LN5lKSzVyPUK0MlM4KG6PMVfTRW5ITVJ?
A172NGnMb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfmTWM2OD1{ND63NUBvVQ>?NEixWZRUSU6JRWK=
MONO-MAC-6MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moi4TWM2OD1{ND64OEBvVQ>?NGHrUZpUSU6JRWK=
NCI-H1650NXHxVVd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTFWHhHUUN3ME2yOU41KG6PMUDTRW5ITVJ?
NH-12M4rzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXpTWM2OD1{NT61JI5ONV;iUGplW0GQR1XS
ML-2MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33sNGlEPTB;MkWuO|Qhdk1?NGnVU2lUSU6JRWK=
MZ2-MELMorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTJ4LkKyJI5OMV3TRW5ITVJ?
COLO-684MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTJ4LkSxJI5OMX\TRW5ITVJ?
HuP-T4NHjwV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\BXJFOUUN3ME2yO{4{KG6PM{fNW3NCVkeHUh?=
SW837NVuwTVJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;CSFBKSzVyPUK3MlYzKG6PMlnEV2FPT0WU
MDA-MB-231MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJ5Lke4JI5ONGW4eVdUSU6JRWK=
KYSE-140MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTJ5LkmxJI5OM2L5Z3NCVkeHUh?=
NOMO-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmj4TWM2OD1{OD62PEBvVQ>?M37PeXNCVkeHUh?=
GP5dNVfqSY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTJ6LkeyJI5OMlGxV2FPT0WU
COR-L105M2n6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTJ7LkSyJI5OM{XneHNCVkeHUh?=
LS-411NMlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTJ7Lki4JI5OMmjjV2FPT0WU
NYM3fKdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTNyLkG4JI5ONWLnOVBkW0GQR1XS
NCI-H2030NYLWTYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LudmlEPTB;M{CuOFUhdk1?MX3TRW5ITVJ?
CCF-STTG1M{mydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDLTWM2OD1|MT60NkBvVQ>?NEfORmdUSU6JRWK=
NCI-H1703M3vqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jGbWlEPTB;M{GuO|ghdk1?M2HhbXNCVkeHUh?=
TURMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjFfIdKSzVyPUOyMlA{KG6PNWLW[ooyW0GQR1XS
NOS-1M4DvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfITWM2OD1|Mj60OEBvVQ>?NVXTXY4xW0GQR1XS
A2058Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTN{LkizJI5OM3nM[3NCVkeHUh?=
LCLC-103HNGLGT3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVj1ZWUxUUN3ME2zN{4zPSCwTR?=NUKySmN[W0GQR1XS
NCI-H510AMljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTN|LkK3JI5OMWDTRW5ITVJ?
BC-1M3L6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLMdZhPUUN3ME2zN{44PyCwTR?=NVnSSIlwW0GQR1XS
SK-CO-1M3zMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnPTWM2OD1|ND6wNUBvVQ>?M3[1dnNCVkeHUh?=
A673NEXCToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfRT45{UUN3ME2zOE4yPyCwTR?=MoqyV2FPT0WU
VM-CUB-1NXLpcWhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGG4R5NKSzVyPUO0MlY6KG6PM3TlTXNCVkeHUh?=
HHMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTN3LkC2JI5OMnrqV2FPT0WU
CAL-27MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPJTWM2OD1|NT6xOkBvVQ>?M3XYXXNCVkeHUh?=
NEC8M3KyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml7QTWM2OD1|NT6zO{BvVQ>?M4P3S3NCVkeHUh?=
BxPC-3MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LNbGlEPTB;M{[uPVEhdk1?MUTTRW5ITVJ?
SNB75M4\EOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU\XeHlpUUN3ME2zO{4zPCCwTR?=MV7TRW5ITVJ?
NB13MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XWSGlEPTB;M{iuNlMhdk1?MWfTRW5ITVJ?
SK-OV-3M3nlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPLWod[UUN3ME2zPE44PCCwTR?=NHvzcJRUSU6JRWK=
ME-180MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTN6Lkigcm0>MlfuV2FPT0WU
JiyoyeP-2003MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\QbGlEPTB;M{muN|ghdk1?MojEV2FPT0WU
LU-134-AMmDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVyxeJNKUUN3ME20NE4xOiCwTR?=MlLBV2FPT0WU
LS-123M4TNXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTRyLkK4JI5ONV\nPG1yW0GQR1XS
COLO-800MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7Cd41zUUN3ME20NE42PiCwTR?=Ml\nV2FPT0WU
LB831-BLCNGrOV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\iWVk{UUN3ME20NU45PSCwTR?=M{DmenNCVkeHUh?=
NCI-H747M2XGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTR{LkK4JI5OMUPTRW5ITVJ?
MZ7-melMkjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;aVlVTUUN3ME20Nk43PiCwTR?=MVPTRW5ITVJ?
GT3TKBMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mnu2TWM2OD12Mj63NkBvVQ>?NGTk[HZUSU6JRWK=
MOLT-16NX\CcG53T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXMdpNQUUN3ME20N{4xPSCwTR?=MUPTRW5ITVJ?
23132-87NHvz[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX74[mxsUUN3ME20N{4xPSCwTR?=MVTTRW5ITVJ?
PF-382NYTLdG81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrCTWM2OD12ND6yNkBvVQ>?NYS4cFlSW0GQR1XS
ES3MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjXVnVKSzVyPUS0MlYhdk1?NV7Nd5ExW0GQR1XS
SW756M4TYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnOwTWM2OD12NT6xOEBvVQ>?NGnHNlJUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.

[2] Bruns CJ, et al. Clin Cancer Res, 2000, 6(5), 1936-1948.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-04-16)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02383433 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Case Comprehensive Cancer Center|National Cancer Institut  ...more Case Comprehensive Cancer Center|National Cancer Institute (NCI) September 2016 Phase 2
NCT02627443 Not yet recruiting High Grade Ovarian Serous Adenocarcinoma|Ovarian Endometrioid Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primar  ...more High Grade Ovarian Serous Adenocarcinoma|Ovarian Endometrioid Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer National Cancer Institute (NCI) August 2016 Phase 2
NCT02722369 Not yet recruiting Small Cell Lung Cancer University College, London August 2016 Phase 2
NCT02567409 Not yet recruiting Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Stage IV Bladder Urothelial Carcinoma National Cancer Institute (NCI) August 2016 Phase 2
NCT02574455 Not yet recruiting Breast Cancer Immunomedics, Inc. July 2016 Phase 3

view more

Chemical Information

Download Gemcitabine SDF
Molecular Weight (MW) 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LY-188011, NSC 613327
Solubility (25°C) * In vitro DMSO 15 mg/mL (56.99 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2'-​deoxy-​2',​2'-​difluoro-cytidine

Customer Product Validation (3)


Click to enlarge
Rating
Source Proc Natl Acad Sci USA, 2015, 112(6): 1839-44. Gemcitabine purchased from Selleck
Method Xenograft Study
Cell Lines Athymic nude mice
Concentrations 120 mg/kg
Incubation Time 14 d
Results Gemcitabine treatment caused a threefold increase in stemness-high cell population.

Click to enlarge
Rating
Source Nucleic Acids Res 2014 42(10), 6436-47. Gemcitabine purchased from Selleck
Method Immunofluorescence
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 72 h
Results To finally investigate whether incorporation of drugs into RNA could be a general mechanism inducing SG assembly, we tested other chemotherapeutics known to incorporate into RNA, such as 5-azacytidine and 6-thioguanine, or as control, chemotherapeutics known to incorporate mainly into DNA, such as trifluorothymidine (TFT) or gemcitabine. HeLa cells treated with 5-azacytidine and 6-thioguanine displayed TIAR-positive foci, whereas HeLa cells treated with TFT or gemcitabine did exhibit such foci even with higher concentrations applied.

Click to enlarge
Rating
Source Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck
Method MTT assays
Cell Lines MCF7 cells, MCF10A cells
Concentrations 0.01-100 μM
Incubation Time 48 h
Results Gemcitabine potently inhibited the survival of MCF10A cells in a dose-dependent manner. The highest level of inhibition was observed with Gemcitabine HCl in concentration of 0.01 μM in MCF7 cells

Product Use Citation (13)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA/RNA Synthesis Products

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Recently Viewed Items

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us